• SPX
  • $5,948.71
  • 0.53 %
  • $31.60
  • DJI
  • $43,870.35
  • 1.06 %
  • $461.88
  • N225
  • $38,283.85
  • 0.68 %
  • $257.68
  • FTSE
  • $8,206.38
  • 0.7 %
  • $57.11
  • IXIC
  • $18,972.42
  • 0.03 %
  • $6.28
IVERIC bio, Inc. (ISEE) Stock Price, News & Analysis

IVERIC bio, Inc. (ISEE) Stock Price, News & Analysis

Currency in USD Disclaimer

NA

NA

NA

Day's range
$39.85
Day's range
$39.98
50-day range
$31.04
Day's range
$39.99
  • Country: US
  • ISIN: US46583P1021
52 wk range
$9.39
Day's range
$39.99
  • CEO: Mr. Glenn P. Sblendorio M.B.A.
  • Website: Visit Site
Notice: This company has been marked as potentially delisted and may not be actively trading.


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score 22.00
  • Piotroski Score 1.00
  • Grade Perform
  • Symbol (ISEE)
  • Company IVERIC bio, Inc.
  • Price $39.95
  • Changes Percentage (0.38%)
  • Change $0.15
  • Day Low $39.85
  • Day High $39.98
  • Year High $39.99

IVERIC bio, Inc., a biopharmaceutical company, discovers and develops novel treatments for retinal diseases with a focus on age-related and orphan inherited retinal diseases (IRDs). The company develops Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; and GATHER2 that is in Phase 3 clinical trial for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD). It also develops STAR or OPH2005 that is in Phase 2b clinical trial for the treatment of leber congenital amaurosis type 10 (LCA10) and autosomal recessive stargardt disease (STGD1); IC-500, a high temperature requirement A serine peptidase 1 protein inhibitors for the treatment of GA and other age-related retinal diseases; IC-100 for the treatment of rhodopsin-mediated autosomal dominant retinitis pigmentosa; and IC-200 for the treatment of IRDs associated with mutations in the BEST1 gene. In addition, the company develops OPH2001 that has completed Phase 1/2a clinical trial of various doses of Zimura monotherapy for the treatment of GA; OPH2000, which has completed Phase 1/2a clinical trial of various doses of Zimura administered in combination with Lucentis for the treatment of wet AMD; OPH2007 that has completed Phase 2a clinical trial for the treatment of wet AMD; and OPH2002, which has completed Phase 2a clinical trial for the treatment of idiopathic polypoidal choroidal vasculopathy. Its discovery and research programs include miniCEP290 program for LCA10; miniABCA4 Program for STGD1; and miniUSH2A Program for usher syndrome type 2A-Related IRDs. The company was formerly known as Ophthotech Corporation and changed its name to IVERIC bio, Inc. in April 2019. The company was incorporated in 2007 and is based in Parsippany, New Jersey.

  • Last Earnings
  • Ex-Dividend for 5/16 Dividend
  • Dividend Payable
  • Today N/A
  • Next Earnings (Estimated) 07/23/2023
  • Fiscal Year End N/A

  • Average Stock Price Target $34.50
  • High Stock Price Target $35.00
  • Low Stock Price Target $27.00
  • Potential Upside/Downside N/A
  • Consensus Rating Neutral
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) -$1.78
  • Trailing P/E Ratio -22.443820224719
  • Forward P/E Ratio -22.443820224719
  • P/E Growth -22.443820224719
  • Net Income $-175,745,000

Income Statement

Quarterly

Annual

Latest News of ISEE

The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

IVERIC bio, Inc. Frequently Asked Questions

  • What were the earnings of ISEE in the last quarter?

    In the last quarter IVERIC bio, Inc. earnings were on Tuesday, July, 25th. The IVERIC bio, Inc. maker reported -$0.41 EPS for the quarter, beating analysts' consensus estimates of -$0.49 by $0.08.

  • What is the IVERIC bio, Inc. stock price today?

    Today's price of IVERIC bio, Inc. is $39.95 — it has increased by +0.38% in the past 24 hours. Watch IVERIC bio, Inc. stock price performance more closely on the chart.

  • Does IVERIC bio, Inc. release reports?

    Yes, you can track IVERIC bio, Inc.'s financials in yearly and quarterly reports directly on Stocks.News.

  • What is the IVERIC bio, Inc. stock forecast?

    Watch the IVERIC bio, Inc. chart and read a more detailed IVERIC bio, Inc. stock forecast to see what analysts suggest you do with its shares.

  • What is IVERIC bio, Inc. stock ticker?

    The stock ticker can vary on the respective exchange. For instance, on NASDAQ, exchange stock trades by IVERIC bio, Inc. stock ticker.

  • How to buy IVERIC bio, Inc. stocks?

    Like other stocks, ISEE shares are sold on stock exchanges such as NASDAQ. The best way to obtain them is through an online stock broker. Open an account, follow the broker's steps, and start trading.

  • What is IVERIC bio, Inc.'s EBITDA?

    IVERIC bio, Inc. measures a company's operating performance, and its growth indicates efficiency improvements. Access more stats in IVERIC bio, Inc.’s financial statements.

  • What is the IVERIC bio, Inc.'s net income ratio for the financial year 2022?

    The net income ratio for the financial year 2022 is 0, which equates to approximately 0.00%. This ratio indicates the percentage of net income generated from total revenue and serves as a key measure of a company’s profitability.

  • Should I invest in IVERIC bio, Inc. stocks?

    Investing in stocks requires thorough research. Carefully examine all available data, including IVERIC bio, Inc.'s financials relevant news, and technical analysis. IVERIC bio, Inc.'s technical analysis shows a “buy” rating today and a one-week “buy” rating. Since market conditions can change, it’s wise to look at longer-term trends — the one-month rating for IVERIC bio, Inc. stock currently indicates a “sell” signal. For more insights, review IVERIC bio, Inc.’s technical analysis.

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to Stocks.News!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.